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Abstract
Background: TFIID is a multiprotein complex that plays a pivotal role in the regulation of RNA polymerase II (Pol
II) transcription owing to its core promoter recognition and co-activator functions. TAF6 is a core TFIID subunit
whose splice variants include the major TAF6a isoform that is ubiquitously expressed, and the inducible TAF6δ.I n
contrast to TAF6a, TAF6δ is a pro-apoptotic isoform with a 10 amino acid deletion in its histone fold domain that
abolishes its interaction with TAF9. TAF6δ expression can dictate life versus death decisions of human cells.
Results: Here we define the impact of endogenous TAF6δ expression on the global transcriptome landscape.
TAF6δ was found to orchestrate a transcription profile that included statistically significant enrichment of genes of
apoptotic function. Interestingly, gene expression patterns controlled by TAF6δ share similarities with, but are not
equivalent to, those reported to change following TAF9 and/or TAF9b depletion. Finally, because TAF6δ regulates
certain p53 target genes, we tested and demonstrated a physical and functional interaction between TAF6δ and
p53.
Conclusion: Together our data define a TAF6δ-driven apoptotic gene expression program and show crosstalk
between the p53 and TAF6δ pathways.
Background
Apoptosis is an active program of cell death that is
required for normal development and tissue homeostasis
in metazoans [1]. The deregulation of apoptotic path-
ways underlies many human diseases [2]. Consequently,
apoptotic pathways represent potential targets for thera-
peutic control of cell death for diseases including neuro-
degenerative disorders, autoimmune diseases and cancer
[3]. Our previous studies have uncovered the existence
of an apoptotic pathway termed the TAF6δ pathway
that controls cell death [4,5].
TAF6δ is an inducible splice variant of the TFIID sub-
unit TAF6 (previously termed hTAFII70 or hTAFII80).
TFIID is a multiprotein complex containing the TATA-
binding protein (TBP) and up to 14 evolutionarily con-
served TBP-associated factors (TAFs) [6,7]. TFIID is the
primary core promoter recognition complex for RNA
polymerase II (pol II) and thus plays a key role in the
regulation of transcription of protein-coding genes [8].
The major TAF6a isoform is ubiquitously expressed [9]
whereas strong expression of the TAF6δ isoform has
only been detected in apoptotic conditions (e.g. HL-60
cells undergoing retinoic acid dependent death) [4]. The
use of modified antisense RNA oligonucleotides, also
termed splice-switching oligonucleotides (SSO), to
experimentally direct the expression of endogenous
TAF6δ in living cells has recently demonstrated the pro-
apoptotic activity of TAF6δ [5].
The major TAF6a isoform contributes to the stability
of core TFIID complexes in part by dimerizing with
TAF9 via its histone fold domain [9-13]. Structurally,
TAF6δ differs from TAF6a only in that it lacks 10
amino acids within its histone fold domain. These
amino acids, however, are critical for the interaction of
TAF6a with TAF9 [14], and as a consequence, TAF6δ
cannot interact with TAF9 [4]. As is the case for TAF9,
the highly homologous protein TAF9b cannot interact
with the pro-apoptotic TAF6δ isoform [15]. TAF6δ does
retain the capacity to interact directly with other TFIID
subunits including TAF1, TAF5, TBP and TAF12.
* Correspondence: Brendan.Bell@USherbrooke.ca
1RNA Group. Département de microbiologie et d’infectiologie, Faculté de
médecine et sciences de la santé, Université de Sherbrooke, 3001 12e ave
Nord, Sherbrooke, Québec J1H 5N4, Canada
Wilhelm et al. BMC Molecular Biology 2010, 11:10
http://www.biomedcentral.com/1471-2199/11/10
© 2010 Wilhelm et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Consequently, within cells TAF6δ is incorporated into a
TFIID-like complex that lacks TAF9 and TAF9b, termed
TFIIDπ [4]. Depletion of TAF9 or the highly homolo-
gous protein TAF9b in HeLa cells has been shown to
alter global gene expression patterns [16]. Presently it is
not known whether the transcriptional effects of TAF6δ
are related to those resulting from the depletion of
TAF9 and/or TAF9b. Our previous work revealed that
TAF6δ can alter gene expression [5], but a physiologi-
cally informative definition of the transcriptome impact
of TAF6δ is currently lacking.
Data documenting a direct interaction between the
major TAF6a isoform with p53 has been shown in vitro
using recombinant proteins [17], in vitro using endogen-
ous human TFIID [18], and in cultured cells using
reporter assays [19]. Furthermore, the interaction of
TAF6a with p53 has been shown to be essential for the
activation of transcription by p53 in vitro [17] as well as
in vivo in mice bearing point mutations within p53 that
block its interaction with TAF6a [20]. Currently it is
not known whether the inducible pro-apoptotic TAF6δ
isoform can interact with p53. Importantly, TAF6δ
induces apoptosis in cell lines that lack p53 expression
[5]. Moreover, the induction of TAF6δ produced similar
levels of apoptosis in the HCT-116 p53 -/- colon carci-
noma cell line as in its p53 positive counterpart [5].
Thus, TAF6δ can induce programmed cell death inde-
pendently of p53, however the functional relationship
between the TAF6δ and p53 pathways requires further
clarification.
The TAF6δ pathway represents a tractable experimen-
tal paradigm to elucidate the mechanisms by which
human cells respond to their environment through sub-
unit changes in the general transcription machinery
[21]. Moreover, there is mounting evidence that the
TAF6δ pathway may be altered in certain cancers. Aber-
rant TAF6 expression has been documented in human
cancers including lung cancer [22,23] and breast cancer
[24,25]. The molecular basis for the induction of apop-
tosis by TAF6δ is currently unknown. In order to shed
further light on the impact of TAF6δ on the human
transcriptome, here we performed a transcriptome-wide
analysis of the impact of endogenous TAF6δ expression
in HeLa cervical carcinoma cells. Our data provide the
first physiologically coherent transcriptome signature for
TAF6δ, establish the relationship of the TAF6δ signature
with those of TAF9/TAF9b, and identify a functional
and physical interaction of TAF6δ with p53.
Results
The TAF6δ orchestrates a pro-apoptotic gene expression
program
To establish the impact of TAF6δ on global gene
expression patterns, the expression of the endogenous
TAF6δ splice variant was experimentally induced using
splice-switching oligonucleotides (SSO) as previously
documented [5]. The HeLa cell line was chosen as a
model system for transcriptome studies for three princi-
ple reasons. Firstly, these cells are readily transfectable
and produce a robust apoptotic response to TAF6δ-
inducing SSO [5]. Secondly, the TAF6δ cDNA was
cloned from a HeLa cell library [4] and therefore these
cells provide a natural cellular context. Thirdly, HeLa
cells express no detectable TAF6δ protein under stan-
dard culture conditions [5], thus these cells provide a
stringently inducible model for SSO studies. To define
the impact of TAF6δ expression on transcriptome
dynamics we took advantage of an experimental
approach that combines SSO treatment with high sensi-
tivity microarray analysis [26]. We note that to achieve
the statistically significant overrepresentation of gene
ontology pathways reported here it was necessary to
employ optimized SSO sequences designed to more effi-
ciently induce TAF6δ expression than those employed
in a previous study [5]. The improved SSO were trans-
fected into HeLa cells and the induction of endogenous
TAF6δ mRNA and protein was confirmed, as shown in
Additional File 1. Total RNA was isolated 18 hours
post-transfection and subjected to microarray analysis as
previously detailed [26]. Biological triplicates were per-
formed with SSO T6-1 and, as a control to normalize
for any non-specific SSO effects, a scrambled oligonu-
cleotide (SSO ctrol). The statistical analysis and filtering
of the raw microarray data was carried out as previously
described [26] to identify significantly (P < 0.05) regu-
lated mRNAs.
The induction of endogenous TAF6δ resulted in sig-
nificant changes in the levels of 961 probes corre-
sponding to 955 independent genes of 27,868 (Figure
1A). Remarkably, 90.5% of the mRNAs significantly
changed by TAF6δ are upregulated and only 9.5% are
downregulated (Figure 1A). T h e s ed a t aa r ec o n s i s t e n t
with previous results obtained with a less efficient SSO
in the HCT-116 cell line [5] and further demonstrate
that TAF6δ acts primarily as a positive regulator of
gene expression. The data also rule out the possibility
that TAF6δ-induced cell death is a result of a global
reduction in mRNA transcription. To validate the
TAF6δ transcriptome signature we selected 14 genes
(and the internal control beta-2-microglobulin gene)
for quantitative RT-PCR confirmation. Gene expres-
sion changes measured by real-time RT-PCR for the
14 genes showed a strong correlation with changes
measured by microarray analysis (Pearson correlation
coefficient R
2 = 0.769, Figure 1B &1C). To further con-
firm the specificity of the TAF6δ transcriptome signa-
ture we employed a distinct TAF6 targeting antisense
oligonucleotide (SSO T6-3), whose binding to the
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stream with respect to SSO T6-1. SSO T6-3 is slightly
more efficient in inducing endogenous TAF6δ than
SSO T6-1 (Additional File 1). Real-time RT-PCR
shows that like SSO T6-1, SSO T6-3 also altered the
expression of the same 14 TAF6δ target genes (Pear-
son correlation coefficient with microarray measure-
ments R
2 = 0.836, Figure 1B &1C). The above data
confirm that the microarray results provide an accurate
and reproducible measure of the TAF6δ-controlled
transcriptome landscape.
To examine the specificity of the TAF6δ-induced tran-
scriptome signature, we compared the microarray data
with those obtained when the pro-apoptotic isoform of
a distinct gene, Bcl-x, was induced by SSO under identi-
cal conditions [5]. As shown in Additional File 2, the
transcriptome signatures resulting from the induction of
TAF6δ and Bcl-xS are highly distinct. The vast majority
of TAF6δ-regulated transcripts (90.5%) were induced
while Bcl-xS expression results in a majority of tran-
scripts being repressed (58%). Only a minor fraction
(3.4%) of the 870 genes upregulated by TAF6δ was also
upregulated by Bcl-xS. Of the small number of tran-
scripts repressed (46) by TAF6δ, 45 are also repressed
by Bcl-xS, possibly reflecting a minor subset of genes
that are repressed by both of these pro-apoptotic path-
ways. The portion of Bcl-xS repressed genes also
repressed by TAF6δ was minor (15.8%). The fact that
genes induced by TAF6δ share little overlap with those
induced by Bcl-xS underscores the highly specific
impact of the TAF6δ-inducing SSO on the
transcriptome.
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Figure 1 Transcriptome analysis following SSO induction of TAF6δ. (A) Expression levels of mRNAs from T6-1 SSO-treated HeLa cells were
individually compared to those from control oligonucleotide-treated HeLa samples by genome-wide microarray analysis. The absolute number
of probes detecting statistically significant (P < 0.05) up- or down-regulation following TAF6δ induction is shown to the left of each bar; the
positive or negative logarithmic (base two) fold-change is shown to the right. The red gradient indicates positive, and the blue gradient
negative fold changes in expression. The relative position of the TAF6δ-regulated genes that were further validated by qPCR (panel B) is
indicated on the right. (B) Independent verification of gene expression changes by quantitative real-time RT-PCR. HeLa cells were transfected
with SSO T6-1 (dark grey bars) or SSO T6-3 (light grey bars) to induce endogenous TAF6δ. 18 hours post-transfection total RNA was analyzed by
quantitative real-time PCR and compared with microarray measurements from HeLa cells transfected with SSO T6-1 (black bars). Error bars
indicate standard deviation of three independent transfections. (C) The Pearson correlation coefficients associated with panel B.
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apoptotic capacity of TAF6δ, we performed gene ontol-
ogy analysis to identify pathways that are statistically
overrepresented within the microarray data (see details
in Materials and Methods). Of 131 cellular pathways
surveyed, those that are statistically (P < 0.05) overrepre-
sented in the TAF6δ data set are the Notch, oxidative
stress response, integrin, p53, apoptosis and p53 path-
way feedback loops 2 pathways (Figure 2A). Genes in
the angiogenesis pathway were also overrepresented (P
= 0.0535, Figure 2A) in the TAF6δ-induced gene pool.
The TAF6δ-regulated genes found in the overrepre-
sented pathways are shown in Additional File 3. We
next postulated that if the pathways activated by TAF6δ
represent a physiologically coherent response, then the
functional connections between these pathways would
not be random. We therefore performed a statistical
analysis to identify pathways that share two or more
genes activated by TAF6δ at frequencies higher than
those expected in a random sample. Statistically signifi-
cant (P < 0.05) overrepresentation of shared genes
between the integrin and angiogenesis pathways, as well
as between the p53 and integrin pathways was observed
(Figure 2B). To provide a visual framework that depicts
the interconnections between the overrepresented path-
ways they were mapped onto cellular signaling networks
using the Pajek algorithm [27]. This global view reveals
that the activated pathways are not randomly distributed
and moreover that there is a network of interconnec-
tions between TAF6δ-regulated pathways, as seen by
black points at which distinct colored lines intersect
(Figure 2C). Taken together, the results above define a
specific TAF6δ-driven transcriptome landscape that
includes the induction of genes in the Notch, oxidative
stress response, integrin, p53, apoptosis, p53 pathway
feedback loops 2 and angiogenesis pathways.
To determine whether or not the changes in mRNA
expression in response to TAF6δ expression result also
in changes in protein levels we selected representative
proteins from the TAF6δ transcriptome signature for
verification by immunoblotting experiments. The micro-
a r r a yd a t as h o w e de x p r e s s i o no fA R N Tm R N Aw a s
repressed by TAF6δ, and immunoblotting showed the
corresponding ARNT protein levels also decreased in
response to TAF6δ-inducing SSO (Figure 3A). The
levels of the transcription factor TBP were tested as a
control for specificity and remained relatively constant
in response to TAF6δ (Figure 3A). The levels of FOS,
JUN, HES1, CDKN2B (p15INK4B), and PMAIP1
(NOXA) were assayed and TAF6δ expression resulted in
increased protein levels that paralleled increased mRNA
levels detected in the microarray experiments in each
case (Figure 3A). Importantly, Bcl-x SSO treatment did
not result in comparable changes of protein levels,
showing the specificity of their response to TAF6δ
expression (Figure 3A). These data demonstrate that for
the proteins tested the impact of TAF6δ on gene expres-
sion programs occurs at both the mRNA and protein
levels, including the induction of the known pro-apopto-
tic protein PMAIP1 (NOXA) [28].
Changes in mRNA levels detected by microarray ana-
lysis can in principle result from a number of effects
including alterations in mRNA stability. To obtain evi-
dence that TAF6δ can regulate gene expression in a
promoter-dependent and promoter-specific fashion, we
tested the ability of endogenous TAF6δ to increase tar-
get gene expression in luciferase reporter gene assays.
We selected four promoters for analysis. The HES1,
DUSP1 and ADM promoters were selected since the
endogenous HES1, DUSP1 and ADM mRNA levels are
induced in response to TAF6δ expression (Figure 1A
&1B). In the case of HES1, the levels of endogenous
HES1 protein were also shown to be induced in
response to TAF6δ expression (Figure 3A). The 3
selected genes act in several of the pathways activated
by TAF6δ including the Notch (HES1) [29], angiogen-
esis (ADM) [30], oxidative stress and p53 pathways
(DUSP1) [31-33]. The Bax promoter was also included
because it is a p53-responsive and pro-apoptotic gene
[34], yet is not induced by TAF6δ.T h ei n d u c t i o no f
TAF6δ in HeLa cells resulted in increased HES1,
DUSP1, and ADM promoter-driven gene expression
(Figure 3B). In contrast, the Bax promoter was not
induced and even measurably repressed (Figure 3B).
These results demonstrate that endogenous TAF6δ can
act directly or indirectly to stimulate transcription in a
promoter-dependent manner.
The TAF6δ transcriptome signature is not equivalent to
those resulting from depletion of TAF9 and/or TAF9b
The only currently known functional distinction
between pro-apoptotic TAF6δ and TAF6a is that
TAF6δ cannot interact with TAF9 or TAF9b. We there-
fore analyzed the extent to which the transcription foot-
prints resulting from TAF6δ induction resembles those
reported following the depletion of TAF9 and/or TAF9b
by treatment with siRNAs in HeLa cells [16]. After map-
ping of the previous microarray data to enable compari-
son with our current microarray platform (see Materials
and Methods), the datasets were co-filtered to compare
transcriptome changes. Of the 961 TAF6δ-dependent
mRNAs selected for comparative analysis, 803 mRNAs
could be mapped between the datasets (Figure 4B). A
global view of the magnitude of the changes for these
803 genes showed that changes in response to TAF6δ
induction were more pronounced than those resulting
from TAF9/TAF9b depletion as depicted by heat maps
(Figure 4A). 204 mRNAs that are statistically signifi-
cantly regulated by TAF9 and/or TAF9b were found
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the 204 genes, 50 showed regulation by both TAF9 and
TAF9b. 90 showed regulation by TAF9 alone and 64
showed regulation by TAF9b alone (Figure 4B). To
probe for communalities between TAF6δ,T A F 9a n d
TAF9b-controlled transcriptomes, pathway analysis was
performed on the genes regulated by TAF6δ and TAF9
as well as genes regulated by TAF6δ, TAF9, and TAF9b.
The only pathway that was statistically significantly
overrepresented in these subsets was the “p53 feedback
loop 2” ontology (Figure 4C). Pathway analysis was also
performed on the TAF9b-dependent gene set alone.
Interestingly, the only pathway that was overrepresented
was angiogenesis, a pathway also overrepresented in the
TAF6δ transcriptome signature (Figure 4D). Finally, we
compared the effects of TAF6δ, TAF9, and TAF9b on
single genes from the subset of 50 genes that respond to
changes in the expression all of TAF6δ,T A F 9 ,a n d
A
Signaling Pathway Count Expect. P-value
Notch 7.83 1.31 3.45 E-4
Oxidat. Stress Resp. 6.18 1.32 1.92 E-3
Integrin 12.13 4.67 2.04 E-3
p53 2.49 8.65 3.00 E-3
Apoptosis 2.85 7.75 1.75 E-2
Angiogenesis 3.06 6.11 5.35 E-2
C
B
Notch
3/43 Apoptosis 0/26 1/19
Angiogenesis 6/70 2/15
-
1/18
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Integrin - 2/12 0/25
- 1/3
Oxidat. Stress Resp. 1/10
Angiogenesis
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Notch
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p53
Connecting Genes
p<0.05 p<0.10
Stress Resp.
p53 feedback L2 0.60 2.75 2.97 E-2
Angiogenesis
Apoptosis
Integrin
Oxid. Stress Resp.
Notch
p53
p53 feed back loops 2
Figure 2 Pathway analysis of the TAF6δ transcriptome signature. (A) Specific cellular pathways are statistically significantly (P < 0.05)
overrepresented in the TAF6δ-regulated transcriptome. “Count” indicates the number of probes within the dataset that corresponds to a given
gene ontology pathway, “Expect.” is the number of probes one would expect to find for a given pathway in a random dataset of identical size.
(B) Interconnectivity analysis reveals statistically significant overrepresentation of shared genes between TAF6δ-affected cellular pathways. Red
and orange indicate highly significant (P < 0.05) and significant (P < 0.10) overrepresentation of shared regulated genes, light grey indicates
present links of low statistical significance between the pathways from B. (C) Interconnectivity between overrepresented pathways (highlighted
in color and listed at right) is shown in a network representation generated using Pajek software [27].
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changes in response to TAF6δ induction and TAF9 or
TAF9b depletion of which 10 examples are shown in
Figure 4D. In contrast, approximately 20% of the
TAF6δ- TAF9- and TAF9b-dependent genes were posi-
tively regulated by TAF6δ induction whereas TAF9 or
TAF9b depletion resulted in their suppression (Addi-
tional File 4). Taken together the analysis shows that
TAF6δ induction has both overlapping and unique
impacts on the transcriptome, when compared to TAF9
and/or TAF9b depletion.
TAF6δ interacts physically and functionally with p53
TAF6a is known to interact with the p53 tumor sup-
pressor protein (see Introduction), but whether the pro-
apoptotic TAF6δ isoform could retain the capacity to
interact with p53 is unknown. Our previous work
demonstrated that TAF6δ induces apoptosis indepen-
dently of p53 [5]. Interestingly, the current transcrip-
tome data show that TAF6δ induces the expression of
several p53 target genes (Figure 2A and Additional File
3). We therefore investigated the capacity of TAF6δ to
interact with p53. Recombinant Histidine tagged TAF6δ
was produced in bacteria and purified by nickel affinity
chromatography. GST tagged p53 was produced and
immobilized on glutathione-sepharose beads. Purified
recombinant TAF6δ and TAF6a were assayed for their
capacities to interact with immobilized GST-p53. As
previously reported [17], TAF6a bound efficiently to
GST-p53 (Figure 5A, lane 3, upper row). Terminal
deoxynucleotidyl transferase (TdT) served as a control
for specificity and did not bind to GST-p53 (Figure 5A,
lane 3, lower row). Purified His-TAF6δ was efficiently
retained by GST-p53 (Figure 5A, lane 3, middle row),
but not by GST alone (Figure 5A, lane 2). Resistance to
high ionic strength buffers can provide a measure of the
strength of protein-protein interactions. We therefore
challenged the p53-TAF6 interactions with 600 mM KCl
washes and found that the interactions were stable in
high salt conditions (Figure 5B). These data show a
direct and selective interaction between TAF6δ and p53
in vitro.
To determine whether the TAF6δ-p53 interaction can
occur in living cells we performed co-immunoprecipita-
tion assays. As endogenous TAF6δ is highly labile and
expressed at very low levels [5], TAF6δ was expressed
by transfection of an expression vector into HCT-116
p53 -/- cells. Exogenous p53 was provided by co-trans-
fection of an expression vector. Immunoprecipitation of
TAF6δ resulted in co-immunoprecipitation of p53 (Fig-
ure 5C, lane 3), in contrast to the negative control
immunoprecipitation of tubulin (Figure 5C, lane 2). In
addition, the reciprocal experiment, immunoprecipita-
tion of p53 resulted in recovery of TAF6δ (Figure 5C,
lane 4). Together, these data show that the interaction
between TAF6δ and p53 can occur in the cellular
context.
We next sought to determine whether the interaction
between TAF6δ and p53 has functional consequences.
We took advantage of the fact that the DUSP1 promoter
is activated by TAF6δ (Figure 3B) and is also activated
by p53 [33]. A reporter construct expressing firefly luci-
ferase under the control of the DUSP1 promoter was
co-transfected with p53 expression vectors, as well as
vectors expressing TAF6 variants. TAF6δ transfection
resulted in enhanced DUSP1 expression when co-trans-
fected with p53 (Figure 5D). A truncated version of
TAF6 that lacks pro-apoptotic activity [4] failed to show
significant co-activation (Figure 5D). The protein levels
resulting from transfected plasmids were determined by
immunoblotting experiments and are shown in Addi-
tional File 5. The data exclude the possibility that higher
levels of TAF6δ protein (compared to the truncated
negative control TAF6) contribute to the activation
levels observed. These data show for the first time that
TAF6δ can interact functionally with p53 to co-activate
DUSP1 gene transcription.
Having established that TAF6δ can interact function-
ally with p53, we next sought to define the role of this
interaction with endogenous TAF6δ and p53. Moreover
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Figure 3 TAF6δ controls protein expression and promoter-
dependent transcription. (A) HeLa cells were treated with control
(ctrol), TAF6δ-inducing (SSO T6-3), or Bcl-xS-inducing (SSO Bcl-x)
splice-switching oligonucleotides. Total protein extracts were
prepared 18 hours post-transfection and fractionated by SDS-PAGE
followed by immunoblot analysis of endogenous protein levels with
antibodies indicated at the left. (B) Promoter-dependent regulation
of transcription by endogenous TAF6δ. HeLa cells were transfected
with 100 to 200 ng of HES1, DUSP1, BAX or ADM promoter-
luciferase constructs. 24 hours post-transfection the cells were
treated with 100 nM TAF6δ-inducing oligonucleotide for another 24
hours before measurement of luciferase activity (y-axis). Results are
expressed as log2 fold change of TAF6δ SSO versus control SSO
treated cells. Error bars indicate standard deviation of three
independent transfections.
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Figure 4 Comparison of the transcriptome effects of TAF6δ with TAF9 and TAF9b. (A) A heat map representation of changes in expression
of 800 mRNAs that could be mapped from the published data resulting from depletion of TAF9 or TAF9b [16] to the TAF6δ-dependent
transcriptome signature shows the global comparison of their respective transcriptome profiles. The red gradient indicates positive, and the blue
gradient negative fold changes in expression. (B) A Venn diagram representation of the transcriptome comparison shows the relationship
between genes significantly regulated by TAF6δ, TAF9 and TAF9b. 803 probes were mapped onto the 961 probe TAF6δ signature. (C)
Overrepresentation of the “p53 feedback loop 2” gene ontology pathway is common to the TAF6δ, TAF9 and TAF9b signatures. Pathway analysis
was performed as described in Materials and Methods for genes significantly regulated by both TAF6δ and TAF9 (left), by all of TAF6δ, TAF9 and
TAF9b (right). P-values for overrepresentation are shown in the table. (D) Overrepresentation of the angiogenesis gene ontology pathway is
common to the TAF6δ, TAF9 and TAF9b transcription signatures. Pathway analysis as in (C). (E) Microarray recorded gene expression changes for
examples of genes similarly regulated by TAF6δ, TAF9 and TAF9b are shown. Error bars indicate standard deviations.
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Page 7 of 15we sought to define the potential crosstalk of TAF6δ
with p53 upon endogenous genes and at the transcrip-
tome-wide level. We therefore revisited microarray data
derived from either wild-type HCT-116 or their p53
negative counterpart HCT-116 p53 -/- in which endo-
genous TAF6δ expression was induced by SSO (http://
www.ncbi.nlm.nih.gov/geo/ under accession number
GSE10795) to test for transcriptional crosstalk between
TAF6δ and p53. We re-filtered the data specifically to
determine the influence of TAF6δ versus TAF6a on
p53-dependent genes. The effects of TAF6 isoforms are
illustrated in Figure 6A, and reveal three classes of
genes. Importantly, 20% of p53-regulated genes (e.g.
CAMK2B & THEDC1) change only in the presence of
TAF6δ (Figure 6B). 53% of the p53-regulated genes
change specifically in the presence of TAF6a, for exam-
ple TNFRSF10C and CHIA (Figure 6C). 25% of p53-
regulated genes, such as FAS and ANGPT2, change
expression in the presence of both TAF6δ and TAF6a
(Figure 6D). The data show that the expression of
TAF6δ versus TAF6a can dictate the outcome of p53-
mediated transcriptional signals.
We also filtered the data to determine the reciprocal
influence of p53 status upon previously identified
TAF6δ-dependent mRNAs [5]. 51% of the TAF6δ-regu-
lated mRNAs changed significantly only in the absence
of p53 (Figure 6E), for example TNFRSF6B (Figure 6F).
9% of the TAF6δ-regulated mRNAs changed indepen-
dently of p53 status, including ACRC (Figure 6F). 40%
of TAF6δ-regulated mRNAs changed significantly only
in cells expressing p53, such as TP53I3 (Figure 6F). In
general the influence of p53 on TAF6δ-dependent tran-
scription was relatively subtle in magnitude, with at
least one exception where the gene LOC342293 dis-
played opposing regulation in presence or absence of
p53 (Figure 6F). Together, the above data establish reci-
procal transcriptional crosstalk between the TAF6δ and
p53 proteins.
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The TAF6δ pathway has emerged as an apoptotic sig-
naling hub [4,5,21], yet the mechanisms by which
TAF6δ promotes apoptosis have remained unknown.
Here we provide a transcriptome-wide microarray analy-
sis that defines the impact of endogenous TAF6δ induc-
tion on gene expression patterns. The TAF6δ
transcriptome footprint showed a predominant role for
TAF6δ in the activation of gene expression, with
approximately 90% of TAF6δ-regulated mRNAs being
induced. Genes annotated as belonging to apoptotic
pathways were found to be statistically overrepresented
in the TAF6δ-induced genes. The data therefore provide
experimental support for a model wherein TAF6δ initi-
ates the apoptotic cascade by inducing pro-apoptotic
gene expression. Examples of apoptotic TAF6δ-induced
genes identified include NOXA and FDXR (Additional
File 3) that both code for proteins that each alone
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Page 9 of 15possess pro-apoptotic activity, are p53 target genes, and
localize to the mitochondria [35-37]. As TAF6δ induces
the expression of hundreds of genes, including estab-
lished pro-apoptotic genes, we propose a model whereby
TAF6δ represents a signaling hub that transduces apop-
totic stimuli to redirect the transcriptional machinery to
tip the balance from an anti- to a pro-apoptotic pro-
gram (Figure 7).
In addition to apoptotic genes the unbiased statistical
analysis of our microarray data revealed overrepresenta-
tion of genes in the Notch, oxidative stress response,
integrin, p53, p53 pathway feedback loops 2, and angio-
genesis pathways. The TAF6δ pathway is an orphan
pathway whose molecular trigger remains unknown.
The novel links between these pathways and TAF6δ
expression provide testable hypotheses for the potential
physiological triggers and functions of TAF6δ. For
example, the identification of p53 target genes prompted
us to test and demonstrate a physical interaction
between TAF6δ and p53 (see below). Within the
TAF6δ-activated transcriptome signature, unbiased sta-
tistical approach showed significant overrepresented
interconnections between these individual signaling
pathways (e.g. integrin and angiogenesis). Additional
support for functional interconnections amongst
TAF6δ-associated pathways comes from interactions
documented in the literature. For example, the Notch
[38] and integrin [39] pathways both play important
roles in angiogenesis. The fact that several of the
TAF6δ-induced pathways converge upon the process of
angiogenesis implies a physiological coherent impact of
TAF6δ on gene expression programs. Interestingly,
many of the pathways associated with TAF6δ expression
play roles in the tumor progression. For example,
angiogenesis is both a key event in tumor progression
and a target for anti-cancer therapies [40]. Our study
therefore provides the rationale to initiate studies to test
the impact of TAF6δ on the process of angiogenesis in
vivo in the future.
The incorporation of TAF6δ into TAF-containing
complexes results in the formation of TFIIDπ that lacks
TAF9 (see Introduction). The currently available evi-
dence is consistent with the lack of TAF9 being the
only difference between canonical TFIID complexes and
TFIIDπ [4], however it is conceivable that the inclusion
of TAF6δ could cause as yet unknown changes in
TFIIDπ subunit composition. TAF6 interacts with TAF9
and the resulting dimeric complex can bind to down-
stream promoter elements (DPEs) [41,42]. To date our
analysis of TAF6δ-responsive promoters has revealed no
statistically significant enrichment of DPEs or any of the
known core promoter element within the promoter
regions of genes induced by TAF6δ (unpublished data).
One mechanistic explanation for the transcriptome
impact of TAF6δ could be that the loss of TAF9 or
TAF9b from TFIID alone drives transcriptional changes.
A prediction of this model is that the transcriptome sig-
natures resulting from depletion of TAF9 and/or TAF9b
by small interfering RNAs would be highly similar to
that resulting from induction of TAF6δ. The compara-
tive transcriptomic analysis we provide shows both over-
lapping and unique features of the TAF6δ versus TAF9/
TAF9b-dependent transcriptomes. Interestingly, TAF9b-
depletion, like TAF6δ i n d u c t i o nr e s u l t e di nt r a n s c r i p -
tome profile with overrepresentation of genes function-
ing in angiogenesis pathways. Gene ontology analysis of
the genes regulated by all of TAF6δ,T A F 9a n dT A F 9 b
showed an overrepresentation of a single ontology
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Page 10 of 15termed the p53 feedback loops 2 pathway, suggesting
overlap in the gene expression programs controlled by
these TAFs. A limitation of the current study is that the
distinct approaches (siRNA versus SSO RNA) and
microarray platforms employed results in the loss of
information. Nevertheless, clear differences were
observed between the transcriptome profiles of TAF6δ
versus TAF9 and TAF9b (Additional File 4). We con-
clude that exclusion of TAF9 and/or TAF9b from
TFIID results in transcriptome changes that share cer-
tain targets with, but that do not fully recapitulate the
TAF6δ transcriptome signature.
The current transcriptomea n a l y s i ss h o w e dt h a t
TAF6δ induces genes in the p53 pathway, a result not
revealed by previous transcriptome analysis of TAF6δ in
HCT-116 cells [5]. Based on the finding that TAF6δ and
p53 can share target genes, we tested and confirmed the
direct physical and functional interaction of TAF6δ with
p53. The impact of endogenous TAF6δ on p53-depen-
dent gene expression was further demonstrated at the
transcriptome-wide level. The reciprocal capacity of
endogenous p53 to influence TAF6δ-mediated transcrip-
tion was also detected, although the magnitude of these
effects was globally more modest. Taken together, the
data show that there is reciprocal crosstalk between the
TAF6δ and p53 pathways. The microarray experiments
measure changes in expression resulting from both
direct and indirect effects of TAF6δ and p53. Therefore,
the crosstalk we have documented includes that result-
ing from the direct TAF6δ- p53 but also that resulting
from indirect transcriptional changes. Given the pre-
vious demonstration that TAF6δ can induce apoptosis
independent of p53 [5], we conclude that TAF6δ pos-
sesses both p53 independent and p53 dependent
activities.
Conclusion
In summary, we report here that the transcriptome
landscape orchestrated by TAF6δ includes the induction
of apoptotic gene expression. The transcriptome data
further uncovered novel links between TAF6δ expres-
sion and the Notch, oxidative stress response, integrin,
p53, p53 feedback loop 2, and angiogenesis pathways.
The TAF6δ-controlled transcriptome landscape was
shown not to be equivalent to those resulting from
depletion of TAF9 and/or TAF9b. Finally, the data
establish a physical and functional interaction between
TAF6δ and the p53 tumor suppressor protein.
Methods
Cell culture
HeLa cells were grown in DMEM containing 2.5% CS
and 2.5% FCS. HCT-116 cells were grown in McCoy’s
media supplemented with 10% FCS.
Transfections
2’-O-methyl-oligoribonucleoside phosphorothioate anti-
sense 20-mers were from Sigma-Proligo. “SSO ctrol”,
“SSO T6-1” [5] and “SSO Bcl-x” [43] have been
described. “SSO T6-3” 5’-CUGUGCGAUCUCUUU-
GAUGC-3’ targets the 3’ part of the alternative exon 2
of TAF6. SSOs were transfected at a final concentration
of 200 nM with lipofectamine 2000 (Invitrogen) as a
delivery agent (1.6 μl/ml) according to the manufac-
turer’s recommendations. Plasmids were transfected
using 1 μl DMRIE-C (Invitrogen) as a delivery agent in
a 24 well plate according to the manufacturer’sr e c o m -
mendations. All transfections were performed in Opti-
MEM medium (Invitrogen).
Plasmids
Plasmids expressing firefly luciferase under control of
the HES1 [29], DUSP1 [33], Bax [44], and ADM [45]
promoters have been described. Plasmids expressing
TAF6a,T A F 6 δ and TAF6ΔAB [4] and p53 or its
mutated form p53R175H [46] have been described. To
construct vectors for bacterial production of His-tagged
TAF6a and TAF6δ proteins, full length cDNAs were
excised from pXJ42-TAFII80a and pXJ42-TAFII80δ(ΔA)
[4] respectively, using NotI and XhoI sites. The NotI
site was filled in by treatment with Klenow enzyme. The
generated fragment was inserted into the SalI and Kle-
now filled HindIII sites of pQE31 vector (Qiagen), gen-
erating pQE31-TAF6a and pQE31-TAF6δ plasmids.
pGST-p53Arg [47] and pGEX4-T-3 (GE Healthcare)
were used for expression of GST-tagged p53 and GST
proteins respectively.
Antibodies
Monoclonal antibodies directed against TAF6δ (37TA-1
& 37TA-2) [4], and TBP (3G3) [48] have been
described. The pan-TAF6 monoclonal antibody was pur-
chased from BD Transduction Laboratories. Antibodies
against ARNT (sc-17811), JUN (sc-1694), FOS (sc-52),
CDKN2B (sc-613) and His probe antibody (sc-803) were
purchased from Santa Cruz Biotechnology. Antibodies
against HES1 (AB5702), PMAIP1 (Ab13654), alpha-
Tubulin (clone B-4-1-2), and p53 (clone PAb1801) were
purchased from Millipore, Abcam, Sigma, and Calbio-
chem respectively.
RT-PCR
RT-PCR conditions and primers for amplification of
both TAF6a and TAF6δ have been described [5].
Immunocytochemistry
Immunolabelling of TAF6δ in fixed cells was performed
as described [5].
Microarray Analysis of Gene Expression
Transcriptome analysis was performed as we previously
detailed [26], using the NeONORM normalization
method with k = 0.20 [49]. The published microarray
data for TAF9 and TAF9b depletion by siRNA were
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Page 11 of 15generated on the Génopole Genomics Platform Stras-
bourg using custom technology. In order to be able to
compare those data directly to data generated from
commercial platforms, the unique probe-set identifiers
were mapped to non-redundant NCBI and Ensemble
gene IDs. Similarly, the AB1700 data generated for this
study or from previous studies on an Applied Biosys-
tems Microarray platform were mapped according to
the published procedure [50] to the same set of gene
IDs. After these mapping procedures >87.9% of unique
probe-set or probe IDs could be directly compared
which corresponds to > 93.2% comparable genes. For
comparative pathway inference analyses the TAF9 and
TAF9b data were mapped to, and treated as if AB1700
data to avoid any potential bias stemming from the use
of different ontology annotation databases.
Gene Ontology (GO) and KEGG annotations were ana-
lyzed using the Panther Protein Classification System
http://www.pantherdb.org to identify functional annota-
tions that were significantly enriched in the different
gene sets when compared to the whole set of genes pre-
sent on the ABI microarray. Note that a given gene can
be assigned to different pathways; in order to reduce
multiple probing biases a gene is weighted by the inverse
of the number of pathways it can be assigned to, leading
to non-natural numbers for the gene counts. P-values are
determined using a binominal distribution and a null
hypothesis of a random set of genes with identical size.
Pathway interconnectivity analysis was performed for the
significantly overrepresented pathways based on genes
that are annotated to be part of any combination of two
of the selected pathways and that were significantly regu-
lated in the subtraction profile analysis. Those numbers
were then compared to the entire set of shared genes,
and P-values were calculated as above.
M i c r o a r r a yd a t af o rt h eg e n es e t sa n a l y z e dh e r e i na r e
provided as Additional Files 3; 6, 7, 8, 9, 10. The tran-
scriptome-wide microarray data for all of the experi-
ments described here were deposited in the M. ACE
database http://mace.ihes.fr under accession numbers:
TAF9/TAF9b: 2833146766
TAF6δ signature: 2937831950; Bcl-x: 2156101006; p53:
2370552334
Real time PCR
Real time PCR was performed as described [5]. RNA
was prepared with using an RNeasy mini Kit (Qiagen). 1
μg of total RNA was reverse transcribed using AMV-RT
(Roche). Real-time PCR was performed in a final 25 μl
reaction on 10 ng of cDNA with 12.5 μl2 ×T a q M a n ®
Universal Master Mix (ABI) and 1.25 μl of the following
20× TaqMan® probes: B2M as the internal control
(Hs99999907_m1), ACRC (Hs00369516_m1), ADM
(Hs00181605_m1), ATF3 (Hs00231069_m1), DDIT3
(Hs00358796_g1), DUSP1 (Hs00610256_g1), EFNA5
(Hs00157342_m1), HES1 (Hs00172878_m1), HOM-
TES-103 (Hs00209961_m1), IFRD1 (Hs00155477_m1),
IL6 (Hs00174131_m1), NR4A2 (Hs00428691_m1),
PFKFb4 (Hs00190096_m1), PMAIP1 (Hs00560402_m1),
or TRIB3 (Hs00221754_m1).
Luciferase assays
Cells were washed with PBS and lysed with Passive lysis
buffer (Promega). The luciferase activity was measured
on a Lumistar luminometer (BMG Labtech), after injec-
tion of 2× Luciferin reagent; 270 μM CoenzymeA, 470
μM D-Luciferin, 530 μM ATP (all from Sigma-Aldrich)
40 mM Tris-Phosphate pH 7.8, 2.14 mM MgCl2,5 . 4
mM MgSO4, 0.2 mM EDTA, 33.3 mM DTT.
Recombinant protein production
Escherichia coli M15 cells were transformed with plas-
mids expressing His-TAF6a and His-TAF6δ fusion pro-
teins and grown to log-phase before induction of
protein expression with 1 mM IPTG (isopropyl-b-d-
thiogalactopyranoside) for 18 h at 16.5°C. The cell pel-
lets were resuspended in Ni buffer composed of 1 M
NaCl, 30 mM Tris pH8.0 and supplemented with 25%
glycerol and 1× Complete protease inhibitor cocktail
(PIC) (Roche) and 0.5 mM PMSF (phenylmethyl-sulfo-
nyl fluoride) and sonicated twice for 5 minutes on ice.
After clarification, the supernatant was loaded on a His-
trap column (GE Healthcare) equilibrated in Ni buffer
containing 10 mM imidazole. The column was sequen-
tially washed with Ni buffer containing 60 mM and 100
mM of imidazole and the proteins were finally eluted
with 250 mM imidazole. Purified proteins were dialysed
against buffer D (20 mM HEPES ph7.9, 100 mM KCl,
20% glycerol, 0.2 mM EDTA).
GST and GST-p53 fusion proteins were produced in
Escherichia coli BL-21 cells by IPTG induction (1 mM)
of a log-phase culture for 3 h. The cell pellets were
resuspended in PBS containing 0.5% Triton X-100 and
sonicated twice for 2 minutes. After clarification, the
supernatant was incubated with glutathione-sepharose
(GE Healthcare) for 1 h 30 at 4°C. The beads were
washed three times in PBS and once in buffer D supple-
mented with 5 mM MgCl2, 0.1% NP40 and EDTA up to
1 mM (buffer D+).
Protein-protein Interactions
GST “pull-down” assays were performed essentially as
previously described [17]. GST- and His-tagged proteins
were pretreated with 0.5 U DNase (Promega) for 10
minutes at 37°C before the interaction assay. Equal
amounts of GST or GST-p53 linked to sepharose beads
were then incubated with His-TAF6a,H i s - T A F 6 δ or
His-TdT for 1 hour at room temperature in buffer D
supplemented with 0.5 μgR N a s eA( U S B )( b u f f e rD + ) .
After four washes with buffer D+ containing 100 mM or
600 mM KCl, bound proteins were analyzed by SDS-
PAGE and immunoblotting.
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Cells were lysed in RIPA buffer (50 mM Tris pH8, 1%
NP40, 0.25% Na deoxycholate, 150 mM KCl, 1 mM
EDTA) supplemented with 1× PIC and 0.5 mM PMSF.
The lysate was diluted 1/10 with IP100 buffer (25 mM
Tris pH8, 5 mM MgCl2, 10% glycerol, 100 mM KCl, 0.1%
NP40, 0.3 mM DTT, PIC, PMSF) and precleared with pro-
teinG-sepharose beads for 2 hours at 4°C. The precleared
lysate was then incubated overnight at 4°C with anti-p53,
anti-TAF6δ or anti-tubulin antibodies immobilized on
protein G-sepharose beads. After extensive washes with
IP100 buffer, complexes were analyzed by SDS-PAGE and
immunoblotting.
Additional file 1: Splice-switching oligonucleotide (SSO) targeting of
TAF6. (A) The region of the TAF6 pre-mRNA that includes two alternative
5’ splice sites (SSs) that produce either the constitutive a splice variant or
the alternative δ splice variant is schematically depicted. Selection of an
intron-proximal a 5’ splice site (SS) results in production of the a isoform
of TAF6 (at right) whereas the selection of the proximal δ 5’ SS results in
the production of the δ isoform (at left). The SSO oligonucleotides (SSO
T6-1 & SSO T6-3) base pair with the alternative exon to force splicing
from the distal 5’ SS and enforce expression of the endogenous TAF6δ
isoform (at left). The protein produced by the major splice variant,
TAF6a, can interact with the TFIID subunit, TAF9 via its histone fold
domain. In contrast, TAF6δ lacks 10 amino acids of helix 2 of its histone
fold motif and therefore cannot interact with TAF9. (B) SSO T6-3 induces
endogenous TAF6δ mRNA expression. HeLa cells were transfected with
antisense oligonucleotides: SSO Ctrol, SSO T6-1 or SSO T6-3. 24 hours
post-transfection total RNA was isolated and subjected to RT-PCR with
primers that amplify both the TAF6a and the alternative TAF6δ mRNAs.
(C) Quantification of TAF6δ expression. Black bars show the percentage
of TAF6δ over total TAF6 mRNA as amplified by RT-PCR as in B and
separated by microfluidity and analyzed using a 2100 Agilent Bioanalyzer.
Light grey bars show the percentage of TAF6δ expressing cells after SSO
transfection as in B except that cells were fixed and stained with an anti-
TAF6δ antibody for immunocytochemistry (ICC) and a minimum of 500
cells were scored for their staining with an anti-TAF6δ antibody.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S1.EPS]
Additional file 2: The transcriptome impact of TAF6δ-inducing
splice switching oligonucleotides (SSO) is highly distinct from the
impact of Bcl-x SSO.T A F 6 δ-inducing SSO microarray data have been
compared with previously documented Bcl-x SSO data [26]. Venn
diagrams show the number of distinct and overlapping genes in the up-
regulated (top) or down-regulated (bottom) gene subsets resulting from
treatment with TAF6δ versus Bcl-x SSO.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S2.EPS]
Additional file 3: TAF6δ Signature.csv. This comma separated value
data file contains a tabular listing of the TAF6δ target genes identified in
this study and their annotation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S3.CSV]
Additional file 4: Differential regulation of gene expression by
TAF6δ versus TAF9/TAF9b. Log base 2 fold changes in gene expression
are represented by black (TAF6δ-regulated), white bars (TAF9-regulated),
or grey (TAF9b-regulated) bars. Error bars show the standard deviations
over three independent experiments and gene symbols are shown at
the bottom.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S4.PS]
Additional file 5: Proteins levels resulting from transfection of TAF6
and p53. HeLa cells were transfected with plasmids expressing TAF6,
p53 or p53 bearing the R175H mutation, and DUSP1-luciferase reporter
constructs. (A) Total protein extracts were prepared 28 hours post-
transfection and fractionated by SDS-PAGE followed by immunoblot
analysis of exogenous protein levels with antibodies indicated at the left.
A representative immunoblot is shown. (B) Protein levels from three
independent transfections were quantitated by phosphoimager analysis
and normalized to Actin levels. Error bars show the standard deviations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S5.PS]
Additional file 6: TAF9 Signature.csv. This comma separated value
data file contains a tabular listing of the TAF9 target genes identified in
this study and their annotation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S6.CSV]
Additional file 7: TAF9b Signature.csv. This comma separated value
data file contains a tabular listing of the TAF9b target genes identified in
this study and their annotation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S7.CSV]
Additional file 8: TAF6δ TAF9 common genes.csv. This comma
separated value data file contains a tabular listing of the common TAF6δ
and TAF9 target genes identified in this study and their annotation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S8.CSV]
Additional file 9: TAF6δ TAF9b common genes.csv. This comma
separated value data file contains a tabular listing of the common TAF6δ
and TAF9b target genes identified in this study and their annotation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S9.CSV]
Additional file 10: TAF6δ TAF9 TAF9b common genes.csv.T h i s
comma separated value data file contains a tabular listing of the
common TAF6δ and TAF9 and TAF9b target genes identified in this
study and their annotation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
10-S10.CSV]
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